Inflammatory Bowel Disease Risk in Patients With Axial Spondyloarthritis Treated With Biologic Agents Determined Using the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis: A MetaAnalysis

The BSRBR-AS is supported by the British Society for Rheumatology and they have received funds for the registry from Pfizer, AbbVie, and UCB. These companies have no input in determining the topics for analysis or the work involved in undertaking it, but they do receive an advance copy of the manuscript on which they may make comments. G.J. Macfarlane, MD (Hons), R. Biallas, MPH, L.E. Dean, PhD, G.T. Jones, PhD, O. Rotariu, PhD, Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen; N.J. Goodson, PhD, Rheumatology Department, Liverpool University Foundation Trust, Liverpool, UK. The authors declare no conflicts of interest relevant to this article. Address correspondence to Prof. G.J. Macfarlane, University of Aberdeen, King's College, Aberdeen AB24 3FX, UK. Email: g.j.macfarlane@abdn.ac.uk. Accepted for publication June 20, 2022.

The BSRBR-AS is supported by the British Society for Rheumatology and they have received funds for the registry from Pfizer, AbbVie, and UCB. These companies have no input in determining the topics for analysis or the work involved in undertaking it, but they do receive an advance copy of the manuscript on which they may make comments. G.J. Macfarlane, MD (Hons), R. Biallas, MPH, L.E. Dean, PhD, G.T. Jones, PhD, O. Rotariu, PhD, Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen; N.J. Goodson, PhD, Rheumatology Department, Liverpool University Foundation Trust, Liverpool, UK. The authors declare no conflicts of interest relevant to this article. Address correspondence to Prof. G.J. Macfarlane, University of Aberdeen, King's College, Aberdeen AB24 3FX, UK. Email: g.j.macfarlane@abdn.ac.uk. Accepted for publication June 20, 2022.

The BSRBR-AS is supported by the British Society for Rheumatology and they have received funds for the registry from Pfizer, AbbVie, and UCB. These companies have no input in determining the topics for analysis or the work involved in undertaking it, but they do receive an advance copy of the manuscript on which they may make comments. G.J. Macfarlane, MD (Hons), R. Biallas, MPH, L.E. Dean, PhD, G.T. Jones, PhD, O. Rotariu, PhD, Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen; N.J. Goodson, PhD, Rheumatology Department, Liverpool University Foundation Trust, Liverpool, UK. The authors declare no conflicts of interest relevant to this article. Address correspondence to Prof. G.J. Macfarlane, University of Aberdeen, King's College, Aberdeen AB24 3FX, UK. Email: g.j.macfarlane@abdn.ac.uk. Accepted for publication June 20, 2022.

The BSRBR-AS is supported by the British Society for Rheumatology and they have received funds for the registry from Pfizer, AbbVie, and UCB. These companies have no input in determining the topics for analysis or the work involved in undertaking it, but they do receive an advance copy of the manuscript on which they may make comments. G.J. Macfarlane, MD (Hons), R. Biallas, MPH, L.E. Dean, PhD, G.T. Jones, PhD, O. Rotariu, PhD, Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen; N.J. Goodson, PhD, Rheumatology Department, Liverpool University Foundation Trust, Liverpool, UK. The authors declare no conflicts of interest relevant to this article. Address correspondence to Prof. G.J. Macfarlane, University of Aberdeen, King's College, Aberdeen AB24 3FX, UK. Email: g.j.macfarlane@abdn.ac.uk. Accepted for publication June 20, 2022.

The BSRBR-AS is supported by the British Society for Rheumatology and they have received funds for the registry from Pfizer, AbbVie, and UCB. These companies have no input in determining the topics for analysis or the work involved in undertaking it, but they do receive an advance copy of the manuscript on which they may make comments. G.J. Macfarlane, MD (Hons), R. Biallas, MPH, L.E. Dean, PhD, G.T. Jones, PhD, O. Rotariu, PhD, Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen; N.J. Goodson, PhD, Rheumatology Department, Liverpool University Foundation Trust, Liverpool, UK. The authors declare no conflicts of interest relevant to this article. Address correspondence to Prof. G.J. Macfarlane, University of Aberdeen, King's College, Aberdeen AB24 3FX, UK. Email: g.j.macfarlane@abdn.ac.uk. Accepted for publication June 20, 2022.

The BSRBR-AS is supported by the British Society for Rheumatology and they have received funds for the registry from Pfizer, AbbVie, and UCB. These companies have no input in determining the topics for analysis or the work involved in undertaking it, but they do receive an advance copy of the manuscript on which they may make comments. G.J. Macfarlane, MD (Hons), R. Biallas, MPH, L.E. Dean, PhD, G.T. Jones, PhD, O. Rotariu, PhD, Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen; N.J. Goodson, PhD, Rheumatology Department, Liverpool University Foundation Trust, Liverpool, UK. The authors declare no conflicts of interest relevant to this article. Address correspondence to Prof. G.J. Macfarlane, University of Aberdeen, King's College, Aberdeen AB24 3FX, UK. Email: g.j.macfarlane@abdn.ac.uk. Accepted for publication June 20, 2022.